Cas No.Product NameDescription
1094614-84-2BIX02188BIX02188 significantly blocks MEK5 catalytic activity with IC50 of 4.3 nM and inhibits ERK5 catalytic activity with IC50 of 0.83 μM.
152121-30-7SB202190SB 202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. SB202190 binds within the ATP pocket of the active kinase (Kd = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms (IC50 = 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38β2 respectively).
606143-52-6SelumetinibSelumetinib is MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nm.
152121-47-6SB203580SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 uM. SB203580 required to block PKB phosphorylation with ab IC50 of 3-5 uM.
284461-73-0Sorafenib Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
212631-79-3PD184352CI-1040 is a selective MEK inhibitor (Ki = 300 nM in vitro).
391210-10-9PD0325901PD0325901 is a selective MEK1 and MEK2 inhibitor.
1094614-85-3BIX 02189BIX02189 blocks MEK5 and ERK5 catalytic activity with IC50 values of 1.5 nM and 59 nM, respectively.
391210-00-7PD318088PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor.
167869-21-8PD98059PD98059 is inhibitor of mitogen-activated protein kinase kinase (MAPKK / MEK).
869357-68-6AZD8330AZD8330 is an orally active, selective MEK inhibitor with an IC50 of 7 nM.
1234480-50-2XMD 8-92XMD8-92 is highly selective ERK5/BMK1 inhibitor (KD values are 80, 190, 600 and 890 nM for BMK1, DCAMKL2, PLK4 and TNK1 respectively).
1195768-06-9Dabrafenib mesylateDabrafenib is a novel, potent, and selective Raf kinase inhibitor that is capableof inhibiting the kinase activity of wild-type B-Raf, B-RafV600Eand c-Raf with IC50 values of 3.2, 0.8, and 5.0 nM, respectively.
934660-93-2CobimetinibCobimetinib(GDC-0973; XL518) is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase.
305350-87-2SL327SL-327 is a cell-permeable vinylogous cyanamide that acts as a selective inhibitor of MEK-1 and MEK-2 (IC50 = 0.18 and 0.22 μM respectively).
1173097-76-1UO126U0126 is inhibitor of both MEK1 and MEK2 with an IC50 of 72 nM and 58 nM respectively.
193746-75-7SB242235SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.
1187431-43-1GSK1120212 Trametinib is a reversible, selective, allosteric MEK1/MEK2 kinase activity inhibitor with IC50 of 0.7 and 0.9 nM for MEK1 and MEK2.
220904-83-6GW5074GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.
312917-14-9SC-202671Selective inhibitor of JNK2 and JNK3 (pIC50 values are 6.7, 6.5, <5.0 and <4.8 for JNK3, JNK2, JNK1 and p38α respectively).

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway